Dave Muoio

By Dave Muoio 03:55 pmFebruary 20, 2018
Roche’s Accu-Chek Connect Diabetes Management App has hit yet another snag with the FDA. On February 15, the agency issued a Class 2 Device Recall for certain software versions of the app due to a bug that could lead users to self-administer inappropriate doses of insulin. Roche issued an update correcting the bug back in June, and has posted notices on the Accu-Chek website urging users to...
By Dave Muoio 03:41 pmFebruary 20, 2018
Optra Health, which produces AI-driven iPhronesis analysis platform for healthcare and life sciences clients, today announced the launch of a new genetics-focused product specially designed for consumers, genetic counselors, and other genomics researchers. The OptraGURU platform combines the AI tech of iPhronesis with the language capabilities of Amazon’s Alexa. Users can speak directly to...
By Dave Muoio 03:16 pmFebruary 19, 2018
Virtual reality and mobile app-enabled caregiver screening were among the winners of the Caregiving for Dementia Innovation Challenge, a recently concluded contest run by AARP Services, Inc. (ASI) and UnitedHealthcare. After receiving 254 contest entries, participants attended three in-person events run by design challenge company OpenIDEO in which they fine-tuned a product designed to support...
By Dave Muoio 12:34 pmFebruary 19, 2018
A connected sensor patch developed by Northwestern University engineers and the Shirley Ryan AbilityLab, a research hospital in Chicago, could allow clinicians to better monitor stroke patients as they recover at home. The sensor is comprised of stretchable electronic technology that is both comfortable for patients to wear and accurate enough for use during rehabilitation, according to...
By Dave Muoio 11:09 amFebruary 19, 2018
Ann Mond Johnson will be taking over as CEO of the the American Telemedicine Association in early March, according to a statement released last week. She previously served as the CEO of Zest Health, served as board chair and advisor to ConnectedHealth, and has a history of entrepreneurship. The CEO position’s previous occupant, Jonathan Linkous, stepped down last year after 24 years at the...
By Dave Muoio 04:49 pmFebruary 15, 2018
Pharma giant Roche is set to acquire oncology EHR software firm Flatiron Health in the first half of 2018, the companies announced today in a statement. Roche will pay an additional $1.9 billion over the millions it had already invested into the company in 2016, and as a result of the deal will control all shares of Flatiron Health. “This is an important step in our personalized healthcare...
By Dave Muoio 04:05 pmFebruary 15, 2018
Insulin dose tool gains CE Mark. DreaMed Diabetes has received a CE Mark for its Type 1-focused clinical decision support (CDS) platform, Advisor Pro. The tool’s algorithms process data from a number of connected diabetes management devices to provide a personalized insulin dosing treatment plan. The software achieved similar glycemic control when compared to medical experts during pilot studies...
By Dave Muoio 01:42 pmFebruary 15, 2018
As new technologies and consumer-focused strategies continue their takeover of the healthcare industry, health systems will have to adjust their care models or be left in the dust. Rewiring an incumbent healthcare enterprise is no easy feat, however, and nearly every decision and assumption made along the way is a potential pitfall that requires an open mind. “Team-based, technology-enabled,...
By Dave Muoio 04:07 pmFebruary 14, 2018
The FDA announced yesterday that it will permit marketing of Viz.ai’s Contact, a clinical decision support (CDS) tool that analyzes CT results and highlights cases that may have experienced a stroke. The CDS application was submitted through the agency’s de novo premarket review pathway, and as such creates a new regulatory classification for similar AI-drived platforms to come. The FDA’s...
By Dave Muoio 10:55 amFebruary 14, 2018
Digital diabetes care company Glooko announced today that its Mobile Insulin Dosing System (MIDS) — an app-driven tool that recommends insulin dose adjustments using data collected directly from a patient’s blood glucose meter — has been cleared by the FDA. The MIDS module allows clinicians to create a customized treatment plan and send it to Type 2 diabetes patients directly through the company’...